胱抑素C作为对比剂肾损伤的早期诊断生物标志物的研究进展  

Research progresses of biomarkers for early diagnosis of contrast-induced acute kidney injury by cystatin C

作　　者：张维峰[1] 沈玲红[1] 何奔[1] 

机构地区：[1]上海交通大学医学院附属仁济医院心内科,上海200127

出　　处：《上海交通大学学报（医学版）》2015年第8期1229-1233,共5页Journal of Shanghai Jiao tong University:Medical Science

摘　　要：随着介入治疗、CT和三维重建新技术的发展及血管内造影剂的使用,对比剂肾损伤(CI-AKI)的发生率显著上升。早期诊断CI-AKI可及时治疗并显著改善患者的预后。然而,血清肌酐(SCr)作为急性肾损伤(AKI)的诊断标志物却有着延后性与不可靠性。随着研究的进展,胱抑素C(Cys C)生物标志物引起了人们广泛关注,为CI-AKI的早期诊断,甚至为预测主要心血管不良事件(MACE)的发生提供了可能。该文对近年来相关Cys C作为早期诊断CI-AKI的标志物及预测MACE的研究作一综述,探讨Cys C的应用可能及前景。With the development of intervention therapy, CT, and three dimension reconstruction technology and the application of intravascular contrast media, the incidence of contrast-induced acute kidney injury （CI- AKI） increased rapidly. Early diagnosis of CI-AKI contributes to timely treatment and significantly improves the prognosis. However, it is lagging and unreliable to use serum creatine （SCr） as a biomarker for the diagnosis of acute kidney injury （AKI）. With the development of research, much attention has been paid to the biomarker of cystatin C （ CysC）, which seems to provide the possibility for the early diagnosis of CI-AKI and predicting the incidence of major adverse cardiac events （ MACE）. This paper reviews recent researches relevant to using CysC as the biomarker for early diagnosis of CI-AKI and prediction of MACE and discusses the possibility and prospect of application of CysC.

关 键 词：对比剂肾损伤 胱抑素C 早期诊断 主要心血管不良事件 

分 类 号：R692.5[医药卫生—泌尿科学]